Mylan Shareholders Say Yes To Upjohn Merger
Shareholder Meeting Had Been Delayed Due To COVID-19 Impact
Mylan and Upjohn are aiming to combine into Viatris by the end of 2020, together ticking off regulatory and financial milestones since the deal was announced in late July last year. Mylan shareholder approval remained a condition for the deal to close – with a previous vote delayed by more than two months due to the COVID-19 pandemic.
You may also be interested in...
Upjohn To Divest Three In Australia To Complete On Viatris
Another regulatory approval for Mylan and Upjohn’s proposed combination into Viatris has been ticked off, with the Australian Competition and Consumer Commission saying it will not oppose the deal after Upjohn agreed to divestments to Aspen Pharmacare.
Mylan Sees COVID-19 Impact On Sales
Mylan has seen its second-quarter performance echo that of its industry peers, with a lift provided by COVID-19 related demand in the first three months of the year balanced out by declines in the second quarter of 2020.
Mylan’s Biosimilars Close In On $1bn Milestone
Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.